Mastocytosis and related disorders

Seminars in Diagnostic Pathology

Volumn 29, Issue 1, 2012, Pages 19-30

  Chiu, April ^a   Orazi, Attilio ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Mast cell disease; Mast cell leukemia; Mastocytosis; Myelomastocytic overlap syndromes

Indexed keywords

ALPHA INTERFERON; CD2 ANTIGEN; CD30 ANTIGEN; CLADRIBINE; CROMOGLYCATE DISODIUM; DASATINIB; GLUCOCORTICOID; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; KETOTIFEN; MIDOSTAURIN; STEM CELL FACTOR RECEPTOR; TRYPTASE;

ABDOMINAL CRAMP; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CELL AGGREGATION; CELL STRUCTURE; CLINICAL FEATURE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; GENE MUTATION; HISTOCHEMISTRY; HUMAN; IMMUNOPHENOTYPING; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOMA; PRIORITY JOURNAL; PUVA; SARCOMA; SKIN PRURITUS; SYSTEMIC MASTOCYTOSIS; URTICARIA PIGMENTOSA;

ANTIGENS, CD2; ANTIGENS, CD30; BONE MARROW; DIAGNOSIS, DIFFERENTIAL; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MAST CELLS; MASTOCYTOSIS, CUTANEOUS; MASTOCYTOSIS, SYSTEMIC; MUTATION; MYELODYSPLASTIC-MYELOPROLIFERATIVE DISEASES; PROTO-ONCOGENE PROTEINS C-KIT; TRYPTASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84856184100     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2011.06.002     Document Type: Article

References (90)

1. Horny H.P., Metcalfe D.D., Bennett J.M. Mastocytosis. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 54-63. IARC Press, Lyon. (ed 2). S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
2. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 2001, 25:603-625.
3. Lawrence J.B., Friedman B.S., Travis W.D., et al. Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991, 91:612-624.
4. Travis W.D., Li C.Y., Bergstralh E.J., et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988, 67:345-368.
5. Czarnetzki B.M., Kolde G., Schoemann A., et al. Bone marrow findings in adult patients with urticaria pigmentosa. J Am Acad Dermatol 1988, 18:45-51.
6. Wolff K., Komar M., Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001, 25:519-528.
7. Chiu A., Nanaji N.M., Czader M., et al. The stromal composition of mast cell aggregates in systemic mastocytosis. Mod Pathol 2009, 22:857-865.
8. Lim K.H., Tefferi A., Lasho T.L., et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood 2009, 113:5727-5736.
9. Pardanani A., Lim K.H., Lasho T.L., et al. WHO subvariants of indolent mastocytosis: Clinical details and prognostic evaluation in 159 consecutive adults. Blood 2010, 115:150-151.
10. Ault P., Lynn A., Tam C.S., et al. Systemic mastocytosis in association with chronic lymphocytic leukemia: A rare diagnosis. Leuk Res 2007, 31:1755-1758.
11. Horny H.P., Sotlar K., Sperr W.R., et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: A histopathological challenge. J Clin Pathol 2004, 57:604-608.
12. Stellmacher F., Sotlar K., Balleisen L., et al. Bone marrow mastocytosis associated with IgM kappa plasma cell myeloma. Leuk Lymphoma 2004, 45:801-805.
13. Sotlar K., Colak S., Bache A., et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010, 220:586-595.
14. Pardanani A., Lim K.H., Lasho T.L., et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009, 114:3769-3772.
15. Miranda R.N., Esparza A.R., Sambandam S., et al. Systemic mast cell disease presenting with peripheral blood eosinophilia. Hum Pathol 1994, 25:727-730.
16. Travis W.D., Li C.Y., Hoagland H.C., et al. Mast cell leukemia: Report of a case and review of the literature. Mayo Clin Proc 1986, 61:957-966.
17. Baghestanian M., Bankl H., Sillaber C., et al. A case of malignant mastocytosis with circulating mast cell precursors: Biologic and phenotypic characterization of the malignant clone. Leukemia 1996, 10:159-166.
18. Torrey E., Simpson K., Wilbur S., et al. Malignant mastocytosis with circulating mast cells. Am J Hematol 1990, 34:283-286.
19. Arredondo A.R., Gotlib J., Shier L., et al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. Am J Hematol 2010, 85:600-606.
20. Sotlar K., Cerny-Reiterer S., Petat-Dutter K., et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 2011, 24:585-595.
21. Valent P., Sotlar K., Horny H.P. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: A differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma 2011, 52:740-744.
22. Brcić L., Vuletić L.B., Stepan J., et al. Mast-cell sarcoma of the tibia. J Clin Pathol 2007, 60:424-425.
23. Chott A., Guenther P., Huebner A., et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol 2003, 27:1013-1019.
24. Horny H.P., Parwaresch M.R., Kaiserling E., et al. Mast cell sarcoma of the larynx. J Clin Pathol 1986, 39:596-602.
25. Kojima M., Nakamura S., Itoh H., et al. Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod Pathol 1999, 12:739-743.
26. Charrette E.E., Mariano A.V., Laforet E.G. Solitary mast cell "tumor" of lung. Its place in the spectrum of mast cell disease. Arch Intern Med 1966, 118:358-362.
27. Kudo H., Morinaga S., Shimosato Y., et al. Solitary mast cell tumor of the lung. Cancer 1988, 61:2089-2094.
28. Mylanus E.A., Wielinga E.W., van de Nes J.A. A solitary manifestation of mastocytosis in the head and neck. Eur Arch Otorhinolaryngol 2000, 257:270-272.
29. Sherwin R.P., Kern W.H., Jones J.C. Solitary mast cell granuloma (histiocytoma) of the lung; a histopathologic, tissue culture and time-lapse cinematographic study. Cancer 1965, 18:634-641.
30. Li C.Y. Diagnosis of mastocytosis: Value of cytochemistry and immunohistochemistry. Leuk Res 2001, 25:537-541.
31. Escribano L., Orfao A., Díaz-Agustin B., et al. Indolent systemic mast cell disease in adults: Immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998, 91:2731-2736.
32. Horny H.P., Sillaber C., Menke D., et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998, 22:1132-1140.
33. Yang F., Tran T.A., Carlson J.A., et al. Paraffin section immunophenotype of cutaneous and extracutaneous mast cell disease: Comparison to other hematopoietic neoplasms. Am J Surg Pathol 2000, 24:703-709.
34. Miettinen M., Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005, 13:205-220.
35. Valent P., Spanblöchl E., Sperr W.R., et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 1992, 80:2237-2245.
36. Escribano L., Díaz-Agustín B., Núñez R., et al. Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Immunol 2002, 127:127-132.
37. Jordan J.H., Walchshofer S., Jurecka W., et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: Evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 2001, 32:545-552.
38. Krokowski M., Sotlar K., Krauth M.T., et al. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: Value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Am J Clin Pathol 2005, 124:560-568.
39. Sotlar K., Horny H.P., Simonitsch I., et al. CD25 indicates the neoplastic phenotype of mast cells: A novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004, 28:1319-1325.
40. Escribano L., Diaz-Agustin B., López A., et al. Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 2004, 58:1-8.
41. Valent P., Cerny-Reiterer S., Herrmann H., et al. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol 2010, 23:369-378.
42. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372.
43. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995, 92:10560-10564.
44. Akin C., Kirshenbaum A.S., Semere T., et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000, 28:140-147.
45. Sotlar K., Fridrich C., Mall A., et al. Detection of c-kit point mutation Asp-816 → Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002, 26:979-984.
46. Sotlar K., Marafioti T., Griesser H., et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000, 53:188-193.
47. Bodemer C., Hermine O., Palmérini F., et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010, 130:804-815.
48. Yanagihori H., Oyama N., Nakamura K., et al. c-kit mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn 2005, 7:252-257.
49. Longley B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 1999, 96:1609-1614.
50. Fletcher J.A., Rubin B.P. KIT mutations in GIST. Curr Opin Genet Dev 2007, 17:3-7.
51. Hodi F.S., Friedlander P., Corless C.L., et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008, 26:2046-2051.
52. Kemmer K., Corless C.L., Fletcher J.A., et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004, 164:305-313.
53. Paschka P., Marcucci G., Ruppert A.S., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol 2006, 24:3904-3911.
54. Escribano L., Akin C., Castells M., et al. Mastocytosis: Current concepts in diagnosis and treatment. Ann Hematol 2002, 81:677-690.
55. Pardanani A., Akin C., Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006, 19:595-615.
56. Butterfield J.H., Tefferi A., Kozuh G.F. Successful treatment of systemic mastocytosis with high-dose interferon-alfa: Long-term follow-up of a case. Leuk Res 2005, 29:131-134.
57. Hauswirth A.W., Simonitsch-Klupp I., Uffmann M., et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leuk Res 2004, 28:249-257.
58. Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J., et al. Cladribine therapy for systemic mastocytosis. Blood 2003, 102:4270-4276.
59. Pardanani A., Hoffbrand A.V., Butterfield J.H., et al. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004, 28:127-131.
60. Tefferi A., Li C.Y., Butterfield J.H., et al. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001, 344:307-309.
61. Patnaik M.M., Rindos M., Kouides P.A., et al. Systemic mastocytosis: A concise clinical and laboratory review. Arch Pathol Lab Med 2007, 131:784-791.
62. Valent P., Akin C., Sperr W.R., et al. Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria. Leuk Res 2003, 27:635-641.
63. Akin C., Fumo G., Yavuz A.S., et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004, 103:3222-3225.
64. Zhang L.Y., Smith M.L., Schultheis B., et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006, 30:373-378.
65. Purtill D., Cooney J., Sinniah R., et al. Dasatinib therapy for systemic mastocytosis: Four cases. Eur J Haematol 2008, 80:456-458.
66. Verstovsek S., Tefferi A., Cortes J., et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008, 14:3906-3915.
67. Gotlib J., DeAngelo D.J., George T.I., et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: Report of a fully accrued phase II trial. ASH Annu Meet Abstracts 2010, 116:316.
68. Sperr W.R., Drach J., Hauswirth A.W., et al. Myelomastocytic leukemia: Evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res 2005, 11:6787-6792.
69. Valent P., Samorapoompichit P., Sperr W.R., et al. Myelomastocytic leukemia: Myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J 2002, 3:90-94.
70. Valent P., Sperr W.R., Samorapoompichit P., et al. Myelomastocytic overlap syndromes: Biology, criteria, and relationship to mastocytosis. Leuk Res 2001, 25:595-602.
71. Samorapoompichit P., Schernthaner G.H., Worda C., et al. Evaluation of neoplastic human mast cells by tryptase-immunoelectron microscopy. Histopathology 2006, 48:247-257.
72. Valent P., Spanblöchl E., Bankl H.C., et al. Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis. Blood 1994, 84:4322-4332.
73. Wimazal F., Sperr W.R., Horny H.P., et al. Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. Am J Hematol 1999, 61:66-77.
74. Care R.S., Valk P.J., Goodeve A.C., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003, 121:775-777.
75. Goemans B.F., Zwaan C.M., Miller M., et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19:1536-1542.
76. Cairoli R., Beghini A., Morello E., et al. Imatinib mesylate in the treatment of core binding factor leukemias with KIT mutations. A report of three cases. Leuk Res 2005, 29:397-400.
77. Cammenga J., Horn S., Bergholz U., et al. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood 2005, 106:3958-3961.
78. Schnittger S., Kohl T.M., Haferlach T., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006, 107:1791-1799.
79. Fritsche-Polanz R., Fritz M., Huber A., et al. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol 2010, 4:335-346.
80. Kohl T.M., Schnittger S., Ellwart J.W., et al. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2005, 105:3319-3321.
81. Beghini A., Peterlongo P., Ripamonti C.B., et al. C-kit mutations in core binding factor leukemias. Blood 2000, 95:726-727.
82. Sperr W.R., Escribano L., Jordan J.H., et al. Morphologic properties of neoplastic mast cells: Delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001, 25:529-536.
83. Horny H.P., Sotlar K., Valent P. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: A review. Pathobiology 2010, 77:169-180.
84. Sperr W.R., Jordan J.H., Baghestanian M., et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001, 98:2200-2209.
85. Maric I., Robyn J., Metcalfe D.D., et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007, 120:680-687.
86. Pardanani A., Reeder T., Li C.Y., et al. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 2003, 27:883-885.
87. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
88. Florian S., Esterbauer H., Binder T., et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res 2006, 30:1201-1205.
89. Böhm A., Födinger M., Wimazal F., et al. Eosinophilia in systemic mastocytosis: Clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol 2007, 120:192-199.
90. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102:3093-3096.